Lumasiran Dosage

Medically reviewed by Drugs.com. Last updated on Jan 2, 2025.

Usual Adult Dose for Primary Hyperoxaluria

Weight at least 20 kg:

• Loading dose: 3 mg/kg subcutaneously once a month for 3 doses
• Maintenance dose: 3 mg/kg subcutaneously every 3 months (quarterly)

Comments:

• Dosing is based on actual body weight.
• The maintenance dose should begin 1 month after the last loading dose.

Use: For the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels

Usual Pediatric Dose for Primary Hyperoxaluria

Weight less than 10 kg:

• Loading dose: 6 mg/kg subcutaneously once a month for 3 doses
• Maintenance dose: 3 mg/kg subcutaneously once a month

Weight 10 to less than 20 kg:

• Loading dose: 6 mg/kg subcutaneously once a month for 3 doses
• Maintenance dose: 6 mg/kg subcutaneously every 3 months (quarterly)

Weight at least 20 kg:

• Loading dose: 3 mg/kg subcutaneously once a month for 3 doses
• Maintenance dose: 3 mg/kg subcutaneously every 3 months (quarterly)

Comments:

• Dosing is based on actual body weight.
• The maintenance dose should begin 1 month after the last loading dose.

Use: For the treatment of PH1 to lower urinary and plasma oxalate levels

Renal Dose Adjustments

Renal dysfunction: No adjustment recommended

Liver Dose Adjustments

Mild or moderate liver dysfunction: No adjustment recommended
Severe liver dysfunction: Data not available

Comments:

• Mild liver dysfunction: Total bilirubin greater than 1 to 1.5 times the upper limit of normal (1 to 1.5 x ULN) or AST greater than 1 x ULN
• Moderate liver dysfunction: Total bilirubin greater than 1.5 to 3 x ULN with any AST
• Severe liver dysfunction: Total bilirubin greater than 3 x ULN with any AST

Precautions

CONTRAINDICATIONS: None

Consult WARNINGS section for additional precautions.

Dialysis

Hemodialysis: No adjustment recommended
Peritoneal dialysis: Data not available

Comments:

• This drug should be administered after hemodialysis if administered on dialysis days.
• This drug has not been studied in patients on peritoneal dialysis.

Other Comments

Administration advice:

• For subcutaneous use
• This drug should be administered by a health care professional.
• Divide injection volumes greater than 1.5 mL equally into multiple syringes.
• Use a sterile 0.3 mL syringe for volumes less than 0.3 mL.
• If using a 0.3 mL (30 unit) insulin syringe, 1 unit is equivalent to 0.01 mL.
• Administer subcutaneous injection into the abdomen, thigh, or the side/back of the upper arms; rotate injection sites; do not inject into scar tissue or reddened/inflamed/swollen areas.
• If injecting into the abdomen, avoid the area around the navel.
• If more than 1 injection is needed for a single dose, ensure injection sites are at least 2 cm apart.
• If a dose is delayed or missed, administer as soon as possible; resume prescribed monthly or quarterly dosing from most recently administered dose.

Storage requirements:

• Store single-dose vial at 2C to 25C (36F to 77F) in original container until ready for use.
• Discard unused portion.

Reconstitution/preparation techniques:

• The manufacturer product information should be consulted.

See also:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer